2025
Surgical Management Strategies for Pericardial Effusion—A Systematic Review
Qasba R, Cangut B, Alhazmi A, Naseer J, Mubasher A, Talapaneni S, Fatima M, Nasir A, Shafqat S, Avilala S, Hameed I. Surgical Management Strategies for Pericardial Effusion—A Systematic Review. Journal Of Clinical Medicine 2025, 14: 4985. PMID: 40725678, PMCID: PMC12295354, DOI: 10.3390/jcm14144985.Peer-Reviewed Original ResearchVideo-assisted thoracic surgerySubxiphoid pericardial windowSurgical management strategiesPericardial effusionPericardial windowSurgical managementLateral thoracotomyEtiology of pericardial effusionPost-cardiac surgeryManagement of pericardial effusionBaseline patient characteristicsPost-procedural complicationsRecurrence of effusionSystematic reviewSurgical management techniquesAccumulation of excess fluidPercutaneous pericardiocentesisMedian ageMedian sternotomyThoracic surgerySubxiphoid approachPatient comorbiditiesAutoimmune diseasesFollow-upPatient characteristics
2024
AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial
Seropian S, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Vusirikala M, Sandmaier B, Pagel J, Desai A, Giralt S. AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s319. DOI: 10.1016/s2152-2650(24)01210-2.Peer-Reviewed Original ResearchAllogeneic hematopoietic cell transplantationR/R AMLHematopoietic cell transplantationFollow-upOverall survivalCell transplantationCC patientsCurative allogeneic hematopoietic cell transplantationOlder patientsControlled phase 3 studiesRefractory acute myeloid leukemiaConventional careMedian overall survivalR/R AML patientsMedian Follow-UpTotal body irradiationBaseline patient characteristicsAcute myeloid leukemiaAnalysis of efficacyOff-target toxicityLong-term survivorsCD45-expressing cellsData cutoffBody irradiationMucositis ratesEfficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Carr T, Moore W, Kraft M, Brusselle G, Castro M, Chupp G, Wechsler M, Hunter G, Lindsley A, Llanos J, Burke L, Chandarana S, Ambrose C. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study. Advances In Therapy 2024, 41: 2978-2990. PMID: 38802635, PMCID: PMC11213736, DOI: 10.1007/s12325-024-02889-8.Peer-Reviewed Original ResearchAnnualized asthma exacerbation rateClinically relevant subgroupsEfficacy of tezepelumabBaseline patient characteristicsUncontrolled asthmaClinically relevant subgroups of patientsPatient characteristicsStandard-of-care therapyRelevant subgroups of patientsTezepelumab reduced exacerbationsRelevant subgroupsPlacebo-controlled studyAsthma exacerbation rateSubgroup of patientsReducing asthma exacerbationsBody mass indexPost Hoc AnalysisNSAID sensitivityDouble-blindExacerbation rateTezepelumabSmoking historyPatient subgroupsPlaceboIntroductionMany patientsTorsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Kapelios C, Greene S, Mentz R, Ikeaba U, Wojdyla D, Anstrom K, Eisenstein E, Pitt B, Velazquez E, Fang J, Investigators T. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circulation Heart Failure 2024, 17: e011246. PMID: 38436075, PMCID: PMC10950535, DOI: 10.1161/circheartfailure.123.011246.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionLVEF groupsKansas City Cardiomyopathy Questionnaire clinical summary scoreMildly reduced left ventricular ejection fractionBaseline left ventricular ejection fractionReduced left ventricular ejection fractionClinical summary scoreHeart failureNo significant differenceEjection fractionClinical outcomesLVEF spectrumSignificant differenceLeft ventricular ejection fraction dataEnd pointsSpectrum of ejection fractionEffect of torsemideRisk of clinical outcomesVentricular ejection fractionStudy end pointBaseline patient characteristicsClinical end pointsSummary scoreAll-Cause MortalityPrevalence of comorbiditiesEfficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection
Feuerstadt P, Allegretti J, Dubberke E, Guo A, Harvey A, Yang M, Garcia-Horton V, Fillbrunn M, Tillotson G, Bancke L, LaPlante K, Garey K, Khanna S. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious Diseases And Therapy 2024, 13: 221-236. PMID: 38236515, PMCID: PMC10828144, DOI: 10.1007/s40121-023-00907-w.Peer-Reviewed Original ResearchRecurrence of CDIHealth-related quality of lifeTreatment successPost Hoc AnalysisAntibiotic treatmentDouble-blind placebo-controlled clinical trialPlacebo-controlled clinical trialBlinded phaseHealth-related qualityProbability of treatment successBaseline to weekOdds of recurrenceBaseline patient characteristicsHealth-related quality of life impactCD3- patientsFecal microbiotaAnalyzed efficacyDifficile infectionEligible patientsPatient characteristicsClinical trialsPlaceboRecurrenceEffective treatmentPatientsEfficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
Strober B, Bachelez H, Crowley J, Elewski B, Gooderham M, Menter A, Strohal R, Chen M, Wu T, Zhan T, Photowala H, Armstrong A. Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 864-872. PMID: 38179809, DOI: 10.1111/jdv.19748.Peer-Reviewed Original ResearchSevere plaque psoriasisLong-term efficacyPlaque psoriasisDisease manifestationsWeek 256Palmoplantar psoriasisSubgroup analysisDurable long-term efficacyOpen-label extension studyBaseline patient characteristicsProportion of patientsBody mass indexInflammatory skin diseaseMultiple clinical manifestationsPASI 90/100Psoriatic manifestationsRisankizumab treatmentBaseline characteristicsPatient characteristicsPsoriasis AreaSkin psoriasisMass indexClinical manifestationsArthritis statusPatient subgroups
2023
366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
Feuerstadt P, Blount K, Guo A, Yang M, García-Horton V, Fillbrunn M, Tillotson G, Gao Y, Dubberke E, Garey K. 366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial. Open Forum Infectious Diseases 2023, 10: ofad500.436. PMCID: PMC10676825, DOI: 10.1093/ofid/ofad500.436.Peer-Reviewed Original ResearchClostridioides difficile infectionGut microbiomeDifficile infectionFerring PharmaceuticalsGut microbiotaSignificant associationRecurrent Clostridioides difficile infectionBaseline patient characteristicsHealth-related qualityMicrobiota dataHealthy gut microbiomeSocial domain scoresQuality of lifeGrant/research supportAnalysis groupBackground RecurrencePatient characteristicsClinical trialsHRQLPatientsWeek 1Domain scoresMixed effects analysisHealthy microbiomeRCDIComprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test resultsAssessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials
Wallach J, Deng Y, Polley E, Dhruva S, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Jeffery M, Lyon T, Ross J, McCoy R. Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials. Clinical Trials 2023, 20: 689-698. PMID: 37589143, PMCID: PMC10843567, DOI: 10.1177/17407745231193137.Peer-Reviewed Original ResearchConceptsBaseline participant characteristicsParticipant characteristicsPrimary endpointSecondary endpointsTrial publicationsMajor adverse cardiovascular eventsPropensity score-matched participantsFirst major adverse cardiovascular eventAdverse cardiovascular eventsBaseline patient characteristicsNonfatal myocardial infarctionOptumLabs Data WarehouseElectronic health record dataRepresentative patient populationHealth record dataCardiovascular eventsClinical characteristicsPatient characteristicsPatient populationMyocardial infarctionExclusion criteriaDrug effectivenessTrialsRecord dataEndpointEffect of inferior vena cava filter placement position on device complications
Grubman S, Kostiuk V, Brahmandam A, Tonnessen B, Mojibian H, Schneider E, Guzman R, Chaar C. Effect of inferior vena cava filter placement position on device complications. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2023, 11: 1165-1174.e2. PMID: 37356713, DOI: 10.1016/j.jvsv.2023.05.020.Peer-Reviewed Original ResearchDevice-related mortalityDeep vein thrombosisIVC thrombosisIVC filtersRenal veinDevice complicationsCause mortalityPulmonary embolismVein thrombosisGroup CInferior vena cava filterAccess site hematomaPrimary end pointBaseline patient characteristicsSingle tertiary centerLong-term complicationsLong-term outcomesMultivariate logistic regressionRisk of thrombosisVena cava filtersLong-term thrombosisDistribution of sexEligible patientsSite hematomaPatient characteristicsPredictors of early weight loss in post‐bariatric surgery patients receiving adjunctive behavioural treatments for loss‐of‐control eating
Smith C, Dilip A, Ivezaj V, Duffy A, Grilo C. Predictors of early weight loss in post‐bariatric surgery patients receiving adjunctive behavioural treatments for loss‐of‐control eating. Clinical Obesity 2023, 13: e12603. PMID: 37257889, PMCID: PMC10524670, DOI: 10.1111/cob.12603.Peer-Reviewed Original ResearchConceptsEarly weight lossAdjunctive behavioral treatmentsPost-bariatric surgery patientsEarly weight changeBaseline patient characteristicsSurgery-related variablesMonths of treatmentWeight lossBehavioral treatmentPatient characteristicsSurgery patientsFirst monthWeight changeTime of surgeryWeight gain groupEating-disorder psychopathologyBariatric surgeryMost patientsAdjunctive treatmentBlack patientsPercent weight lossPsychiatric comorbidityClinical variablesTreatment trialsPatientsOptimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine
Jetsupphasuk M, Hudgens M, Lu H, Cole S, Edwards J, Adimora A, Althoff K, Silverberg M, Rebeiro P, Lima V, Marconi V, Sterling T, Horberg M, Gill M, Kitahata M, Moore R, Lang R, Gebo K, Rabkin C, Eron J. Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine. American Journal Of Epidemiology 2023, 192: 1341-1349. PMID: 36922393, PMCID: PMC10666965, DOI: 10.1093/aje/kwad057.Peer-Reviewed Original ResearchConceptsEfavirenz-based regimenAntiretroviral therapyPatient characteristicsComposite outcomeNorth American AIDS Cohort CollaborationFirst-line antiretroviral therapySerious non-AIDS eventsHuman immunodeficiency virus (HIV) treatmentIntegrase strand transfer inhibitorsSame drug regimenBaseline patient characteristicsNon-AIDS eventsAbsolute risk reductionSubgroup of patientsHuman immunodeficiency virusIndividual patient characteristicsImmune deficiency syndromePrecision medicineStrand transfer inhibitorsCohort CollaborationCause mortalityDrug regimenClinical outcomesImmunodeficiency virusDeficiency syndromeOutcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Takemura K, Lemelin A, Ernst M, Wells C, Basappa N, Szabados B, Powles T, Davis I, Wood L, Kapoor A, McKay R, Lee J, Meza L, Pal S, Donskov F, Yuasa T, Beuselinck B, Gebrael G, Choueiri T, Heng D. Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2023, 41: 600-600. DOI: 10.1200/jco.2023.41.6_suppl.600.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumFirst-line therapyRenal cell carcinomaAssociated with longer OSAnti-VEGF monotherapyAnti-VEGFBrain metastasesOutcomes of patientsBaseline patient characteristicsStable diseaseComplete responsePartial responseOverall survivalCombination therapyStereotactic radiosurgeryLonger OSLocal therapyPatient characteristicsInitiation of first-line therapyBest overall responseWhole-brain radiotherapyCohort of patientsProportion of patientsCell carcinomaDisease sites
2022
Pathologic Findings on Hip Arthroscopy in High-Level Athletes Competing in Flexibility Sports
Saks BR, Monahan PF, Maldonado DR, Jimenez AE, Ankem HK, Sabetian PW, Lall AC, Domb BG. Pathologic Findings on Hip Arthroscopy in High-Level Athletes Competing in Flexibility Sports. The American Journal Of Sports Medicine 2022, 50: 1028-1038. PMID: 35254862, DOI: 10.1177/03635465221077002.Peer-Reviewed Original ResearchConceptsFemoroacetabular impingement syndromeHigh-level athletesPatient-reported outcome measuresHip arthroscopyHip scoreTeres tearsOutcome measuresHip Outcome Score-Sports Specific SubscalePropensity score-matched cohortPropensity scoreCartilage lesionsSport competition levelBaseline patient characteristicsHarris hip scoreNonarthritic Hip ScorePrimary hip arthroscopySignificant clinical improvementTime of surgeryBody mass indexVisual analog scaleLigamentum teres tearsLevel of evidenceHigh rateFlexibility sportsNFS group
2021
Patient representativeness of a peripheral artery disease cohort in a randomized control trial versus a real-world cohort: The CLEVER trial versus the PORTRAIT registry
Scierka LE, Jelani QU, Smolderen KG, Gosch K, Spertus JA, Mena-Hurtado C, Jones P, Dreyer RP. Patient representativeness of a peripheral artery disease cohort in a randomized control trial versus a real-world cohort: The CLEVER trial versus the PORTRAIT registry. Contemporary Clinical Trials 2021, 112: 106624. PMID: 34793986, DOI: 10.1016/j.cct.2021.106624.Peer-Reviewed Original ResearchConceptsOptimal medical therapyPeripheral artery diseasePatient characteristicsBaseline patient characteristicsPAD cohortPAD populationPORTRAIT registryExercise therapyPAD patientsPAD symptomsArtery diseaseFinal cohortMedical therapyProspective studyBurdensome diseaseControl trialHealth statusPatientsTherapyCohortCLEVER studyDiseaseMulticenterRevascularizationRCTsPreliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)
Alavi A, Krishnamurti L, Abedi M, Galeon I, Reiner D, Smith S, Wang L, Ramezi A, Rendo P, Walters M. Preliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD). Blood 2021, 138: 2930. DOI: 10.1182/blood-2021-151650.Peer-Reviewed Original ResearchSickle cell diseaseVaso-occlusive crisisAdverse eventsAutologous CD34Apheresis cyclesWeek 26Cell diseaseSpeakers bureauTotal HbOngoing phase 1/2 studySevere sickle cell diseaseF cellsPhase 1/2 studyBaseline patient characteristicsRelated adverse eventsHealth-related qualityPeripheral blood WBCCurrent unmet needPotential therapeutic valueEarly termination visitMinimum cell doseStem cell engraftmentTrend of improvementCurrent employmentElevated fetal hemoglobinTRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Mell L, Spencer S, Stokes W, Yao M, Mitchell D, Harris J, Curran W, Le Q. TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). Journal Of Clinical Oncology 2021, 39: 6014-6014. DOI: 10.1200/jco.2021.39.15_suppl.6014.Peer-Reviewed Original ResearchProgression-free survivalPhase II trialOverall survivalStage IIIII trialArm AGrade 3Treatment-related grade 3Randomized phase II trialFinal analysisEffects of chemoradiationBaseline patient characteristicsDays of therapyAdverse event ratesSurvival of patientsCycles of CDDPLog-rank testDual EGFRA vs BMucositis ratesRash ratesPFS ratePrimary endpointSecondary endpointsFrontline therapyPreoperative MRI and LDH in women undergoing intra-abdominal surgery for fibroids: Effect on surgical route
Kim A, Boyd L, Ringel N, Meyer J, Bennett G, Lerner V. Preoperative MRI and LDH in women undergoing intra-abdominal surgery for fibroids: Effect on surgical route. PLOS ONE 2021, 16: e0246807. PMID: 33561167, PMCID: PMC7872248, DOI: 10.1371/journal.pone.0246807.Peer-Reviewed Original ResearchConceptsAbnormal magnetic resonance imagingMagnetic resonance imaging resultsIntra-abdominal surgeryMagnetic resonance imagingPower morcellationSurgical routeAbnormal magnetic resonance imaging resultsOpen approachResonance imagingSerum lactate dehydrogenase levelPost-protocol groupPre-protocol groupRetrospective cohort studyBaseline patient characteristicsSubset of womenPost-menopausal womenLactate dehydrogenase levelsHigh-risk casesPreoperative magnetic resonanceDiffusion-weighted imagingHigh rateImaging resultsSymptomatic fibroidsChart reviewCohort study
2020
Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, Fernández-Bertolín S, Aragón M, DuVall SL, Lynch K, Falconer T, van Bochove K, Sung C, Matheny ME, Lambert CG, Nyberg F, Alshammari TM, Williams AE, Park RW, Weaver J, Sena AG, Schuemie MJ, Rijnbeek PR, Williams RD, Lane JCE, Prats-Uribe A, Zhang L, Areia C, Krumholz HM, Prieto-Alhambra D, Ryan PB, Hripcsak G, Suchard MA. Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. The Lancet Digital Health 2020, 3: e98-e114. PMID: 33342753, PMCID: PMC7834915, DOI: 10.1016/s2589-7500(20)30289-2.Peer-Reviewed Original ResearchAngiotensin receptor blockersCalcium channel blockersAcute respiratory distress syndromeAcute kidney injuryHospital admissionRespiratory distress syndromeCOVID-19 diagnosisKidney injuryDistress syndromeDrug classesCohort analysisCOVID-19Renin-angiotensin system blockersThiazide-like diureticsBaseline patient characteristicsUse of ACEIsPost-authorisation studiesUK National InstituteRelative risk differenceNational InstituteCombination useMedical Research CouncilAustralian National HealthElectronic health recordsAntihypertensive usersFecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry
Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology 2020, 160: 183-192.e3. PMID: 33011173, PMCID: PMC8034505, DOI: 10.1053/j.gastro.2020.09.038.Peer-Reviewed Original ResearchConceptsClostridioides difficile infectionMicrobiota transplantationSafety profileNational registryProspective real-world studyFull safety profileProspective safety dataBaseline patient characteristicsInflammatory bowel diseaseIrritable bowel syndromeFecal microbiota transplantationLong-term safety outcomesGood safety profileReal-world studyAbdominal painBowel syndromePatient characteristicsReal-world practiceBowel diseaseCDI recurrenceDifficile infectionSafety dataSafety outcomesEffectiveness outcomesSevere symptoms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply